Browse the evidence

Mitochondrial uncoupling promotes energy dissipation and may serve as a strategy for obesity treatment.

Practitioners may consider mitochondrial uncoupling as a potential target for obesity interventions.

Metabolic drugs such as GLP-1-based therapies and SGLT2 inhibitors have benefits that extend beyond metabolic improvements into changes in chronic inflammation.

Practitioners should consider the anti-inflammatory potential of metabolic drugs in clinical settings.

The review discusses emerging therapeutic strategies for MASLD and its associated comorbidities.

Practitioners should stay informed about new treatment options for MASLD and its comorbidities.

Pharmacological classes of metabolic drugs have unexpected and often beneficial effects on cardiovascular outcomes.

Consider the use of metabolic drugs in managing cardiovascular health.

A maladaptive adipokine milieu is associated with endothelial dysfunction, myocardial stiffening, and muscle atrophy in HFpEF.

Recognizing this cycle can inform targeted interventions.

Several classes of medications have been explored to target different pathways and receptors to preserve lean body mass during weight loss.

Practitioners may consider pharmacological options to help preserve muscle mass during weight loss.

Recent progress in glucose-responsive systems enables real-time, glucose-triggered therapeutic activation.

This technology could lead to more effective and responsive diabetes treatments.

Participants assigned a plant-based diet for phase 1 did not see an increase in TMAO during their subsequent animal-meat phase.

Dietary sequencing may influence TMAO levels and cardiovascular risk.

Around 50 significant metabolites and 12 significant microbiota genera correlated with TMAO.

Understanding these correlations may help in developing targeted therapies for CVD prevention.

Orlistat's peak concentration stayed below 5 ng/mL, indicating minimal systemic absorption.

The low systemic absorption suggests a reduced risk of systemic side effects from orlistat.

Dual agonists provide additive and potentially synergistic metabolic benefits through complementary receptor activation.

Practitioners may explore the use of dual agonists for enhanced metabolic outcomes in patients.

Tirzepatide improves β-cell function in T2D patients by reprogramming stressed β cells and restoring β-cell identity through FOXO1-dependent transcriptional reactivation.

Practitioners may consider tirzepatide as a therapeutic option for improving β-cell function in T2D patients.

Emerging therapeutic approaches aim to engage multiple bioenergetic pathways to restore metabolic equilibrium.

Practitioners should consider multi-target approaches in developing treatments for metabolic dysfunction.

Adipose tissue browning is linked to improved metabolic and cardiovascular health.

Promoting adipose tissue browning may enhance metabolic and cardiovascular health.

White adipose tissue browning mitigates inflammation and improves cardiometabolic health.

Encouraging white adipose tissue browning may reduce inflammation and enhance cardiometabolic health.

Modern pharmacotherapies are fundamental to CKD prevention.

Incorporate modern pharmacotherapies into CKD prevention strategies.

The Mediterranean Adequacy Index (MAI) is inversely correlated with the Atherogenicity (ATI) index (R = -0.91).

Practitioners should consider the MAI as a significant dietary factor in cardiovascular health.

Atherogenicity (ATI) is directly correlated with serum cholesterol (R = +0.73).

Practitioners should monitor serum cholesterol levels in relation to dietary fatty acid intake.

Atherogenicity (ATI) and Thrombogenicity (THI) indices are strongly associated with long-term coronary heart disease (CHD) mortality.

Practitioners should consider the impact of dietary fatty acids on long-term CHD risk.

Reduced microbial diversity in the gut is implicated in several gastrointestinal diseases and cancers.

Maintaining gut microbiome diversity may be crucial for preventing gastrointestinal diseases.

Promising candidates such as danuglipron and lotiglipron were discontinued due to hepatotoxicity.

Practitioners should be aware of safety concerns associated with certain GLP-1 receptor agonists.

Artificial intelligence (AI) is a pivotal tool in drug discovery for developing next-generation anti-obesity therapeutics.

Practitioners should consider integrating AI tools in their drug discovery processes for obesity treatments.

Variant screening of PYY 3–36 led to the development of highly selective long-acting analogs against the Y 2 receptor.

This suggests potential for new treatments targeting the Y 2 receptor in diabetes.

BGM1812 was developed through a step-by-step modification process guided by structure-based drug design and molecular dynamics simulations.

Understanding the development process can inform future drug design strategies.